GITNUX MARKETDATA REPORT 2024
Wegovy Weight Loss Duration Statistics
On average, participants in clinical trials of Wegovy experienced significant weight loss over a duration of 68 weeks.
Statistic 1
"In a comparative study, Wegovy demonstrated superior weight loss compared to other GLP-1 receptor agonists."
Statistic 2
"About 50% of patients using Wegovy maintained significant weight loss one year after stopping the medication."
Statistic 3
"Common side effects of Wegovy include nausea, diarrhea, and vomiting, generally peaking during the initial weeks of treatment."
Statistic 4
"Wegovy treatment leads to an average reduction of 10 mmHg in systolic blood pressure."
Statistic 5
"Participants in clinical trials taking Wegovy lost an average of 14.9% of their baseline body weight after 68 weeks."
Statistic 6
"Wegovy works by mimicking the hormone GLP-1, which regulates appetite and food intake."
Statistic 7
"Wegovy also resulted in a mean increase of HDL ("good" cholesterol) levels by 5% after 68 weeks."
Statistic 8
"Roughly 70% of people treated with Wegovy experienced a reduction in HbA1c levels, indicating improved blood sugar control."
Statistic 9
"Wegovy has been reported to reduce waist circumference by an average of 8 cm after 68 weeks."
Statistic 10
"Approximately 86% of participants in a clinical trial achieved at least a 5% reduction in body weight with Wegovy."
Statistic 11
"Wegovy (semaglutide) has been shown to help individuals lose an average of 15-20% of their body weight in clinical trials."
Statistic 12
"Most weight loss with Wegovy happens within the first 16-28 weeks of treatment."
Statistic 13
"Around 32% of individuals using Wegovy achieved weight loss of 20% or more after 68 weeks."
Statistic 14
"Wegovy received FDA approval for long-term weight management in June 2021."
Statistic 15
"Over 60% of participants experienced mild to moderate gastrointestinal adverse events during Wegovy treatment."
Statistic 16
"In clinical trials, Wegovy users saw a reduction in visceral fat by an average of 14% over 68 weeks."
Statistic 17
"Wegovy is typically taken once a week via subcutaneous injection over a period of 68 weeks in clinical studies."
Statistic 18
"Wegovy has shown improvements in cardiovascular risk factors, such as lowering blood pressure and cholesterol levels, in clinical trials."
Statistic 19
"In a study, about 85% of participants treated with Wegovy reduced their waist circumference by at least 5% after 68 weeks."
Statistic 20
"Weight loss with Wegovy was accompanied by statistically significant reductions in triglycerides and inflammatory markers."
Health And Wellness Statistics: Explore more posts from this category
Wegovy Weight Loss Duration Statistics
Weight Loss Duration Statistics
Tooth Loss Frequency Statistics
Vasectomy Driving Downtime Statistics
Vivid Dream Duration Post-Weed Cessation Statistics
Small Tattoo Healing Time Statistics
Smiley Piercing Healing Period Statistics
Smooth Move Tea Effectiveness Duration Statistics
Supplement Companies Reputation Statistics